Sensyne PLC’s new patient data analytics platform SENSIGHT can help double the AIM-listed’s group value according to the house broker Liberum.
SENSIGHT will cost subscribers £25,000 per user per annum and initially gives access to a database of 2m patient records.
The depth of the product will rapidly grow, however, believes Liberum, reaching 10mln by year-end, and accelerating thereafter.
“Given Sensyne now has contracts in place to access 64mln patient real world and trial datasets, we expect the curated database within SENSIGHT to grow rapidly in coming years and likely surpass 100m patients by 2024.“
Early adopter subscribers should be signed in the next few months and commercialisation of the database will quicken rapidly over the next few years, adds the broker.
Liberum describes SENSIGHT as similar to a Bloomberg terminal– a desktop tool allowing deep analysis of the data, creating insightful reports that can be shared, if desired, between subscribers.
The initial datasets within SENSIGHT will have three specialisms: Heart failure; stroke and haematological cancers, however, as the validated database expands Sensyne hopes to add a further 6 disease areas by year-end, and ultimately to cover most disease areas.
Ona cash flow basis, Liberum currently has a share price target of 310p and a buy rating.